Xention Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Out of Business

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Out of Business

Xention General Information

Description

Developer of novel therapies intended to improve the treatment of atrial fibrillation. The company's therapies develop drug candidates that modulate two novel but well-characterized, ion channels to develop breakthrough products in this area of huge unmet medical need, enabling healthcare sector to use channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder, pain, and autoimmune diseases.

Contact Information

Website
www.xention.com
Formerly Known As
Xention Discovery
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 38 High Street
  • Newmarket
  • Suffolk CB8 8LB
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 38 High Street
  • Newmarket
  • Suffolk CB8 8LB
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xention Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Out of Business 01-Jan-2023 Completed Out of Business
9. Secondary Transaction - Private Completed Generating Revenue
8. Later Stage VC 01-Mar-2015 Completed Generating Revenue
7. Later Stage VC 18-Oct-2012 Completed Generating Revenue
6. Later Stage VC (Series D) 23-Nov-2010 Completed Generating Revenue
5. Later Stage VC 25-Jun-2010 Completed Generating Revenue
4. Later Stage VC 31-Mar-2008 Completed Generating Revenue
3. Early Stage VC (Series B) 18-Jul-2005 Completed Startup
2. Early Stage VC 10-Sep-2003 $6.34M $12.6M Completed Startup
1. Early Stage VC 01-Aug-2002 $6.24M $6.24M Completed Startup
To view Xention’s complete valuation and funding history, request access »

Xention Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
D Preferred
To view Xention’s complete cap table history, request access »

Xention Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapies intended to improve the treatment of atrial fibrillation. The company's therapies develop d
Drug Discovery
Suffolk, United Kingdom
13 As of 2016

Boston, MA
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xention Competitors (106)

One of Xention’s 106 competitors is Vertex Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
AnTolRx Formerly VC-backed Cambridge, MA
Minerva Neurosciences Formerly VC-backed Burlington, MA
hVIVO Formerly VC-backed London, United Kingdom
Otonomy Formerly VC-backed San Diego, CA
You’re viewing 5 of 106 competitors. Get the full list »

Xention Patents

  • 134

    Total Documents Applications and Grants

  • Total Patents Families

  • 43

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Xention Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201215284-D0 Compounds Inactive 28-Aug-2012
GB-201214250-D0 Compounds Inactive 09-Aug-2012
US-20140357662-A1 Thieno (2,3 - c) pyrazoles for use as potassium channel inhibitors Inactive 15-Nov-2011
CA-2855346-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Inactive 15-Nov-2011
US-20160152634-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Inactive 15-Nov-2011 C07D495/04
To view Xention’s complete patent history, request access »

Xention Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Xention FAQs

  • When was Xention founded?

    Xention was founded in 2002.

  • Where is Xention headquartered?

    Xention is headquartered in Suffolk, United Kingdom.

  • What is the size of Xention?

    Xention has 13 total employees.

  • What industry is Xention in?

    Xention’s primary industry is Drug Discovery.

  • Is Xention a private or public company?

    Xention is a Private company.

  • What is Xention’s current revenue?

    The current revenue for Xention is .

  • How much funding has Xention raised over time?

    Xention has raised $53.3M.

  • Who are Xention’s competitors?

    Vertex Pharmaceuticals, AnTolRx, Minerva Neurosciences, hVIVO, and Otonomy are some of the 106 competitors of Xention.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »